Clinical trials: Parkinson Disease
Multiple System Atrophy (MSA), Parkinson's Disease (PD)
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.
- Trial name
- NCT07604116
- Testing
- SST001
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Synusight Biotech (Shanghai) Co., Ltd.
Parkinson's Disease (PD)
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of 4 weeks of continuous infusion with ABBV-951 in adult subjects with Parkinson's Disease (PD).
- Trial name
- NCT03374917
- Testing
- ABBV-951
- Where
- 12 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbbVie
Parkinson's Disease
A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (0.5 mg or 1 mg/day) as an add-on to levodopa in Japanese participants with Parkinson's disease with wearing-off phenomenon.
- Trial name
- NCT02337738
- Testing
- TVP-1012 1mg, TVP-1012 0.5mg
- Where
- 57 sites in Japan
- Volunteers
- 404 people
- Sponsor
- Takeda
Parkinson's Disease
An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination.
An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy
- Trial name
- NCT07777484
- Testing
- TRB-001
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Tridem Bioscience FlexCo
Parkinson Disease
DB RCT for Specialized Phototherapy in Parkinson's Disease.
This is a pivotal study to determine whether light therapy can improve non-motor and motor function in Parkinson's disease, on top of current best medical treatment.
- Trial name
- LIGHT-PD (NCT04453033)
- Testing
- Celeste Specialized Phototherapy Device
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- PhotoPharmics, Inc.
Idiopathic Parkinson's Disease
Vercise Implantable Stimulator for Treating Parkinson's Disease
The purpose of this study is to document patient outcomes, including effectiveness, safety, and health economic data, for the Boston Scientific implantable deep brain stimulation (DBS) Vercise™ system for bilateral stimulation of…
- Trial name
- VANTAGE (NCT01221948)
- Testing
- Deep Brain Stimulation
- Where
- 7 sites in Austria, France and 4 more
- Volunteers
- 53 people
- Sponsor
- Boston Scientific Corporation
Non-small Cell Lung Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat…
- Trial name
- NCT06345729
- Testing
- Calderasib, Pembrolizumab
- Where
- 246 sites in United States, Argentina and 28 more
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)
The primary purpose of the study is to evaluate the safety and tolerability of single ascending doses of UCB7853 in healthy male study participants and to evaluate the safety and tolerability of multiple ascending doses of…
- Trial name
- NCT04651153
- Testing
- UCB7853
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Parkinson Disease
ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease
Evaluate the safety and efficacy of unilateral focused ultrasound pallidotomy using the ExAblate 4000 System in the management of dyskinesia symptoms or motor fluctuations for medication refractory, advanced idiopathic…
- Trial name
- NCT03319485
- Testing
- ExAblate Pallidotomy
- Where
- 20 sites in United States, Canada and 6 more
- Volunteers
- 92 people
- Sponsor
- InSightec
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS)…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT04210115
- Testing
- pembrolizumab, cisplatin, 5-FU
- Where
- 170 sites in United States, Argentina and 25 more
- Volunteers
- 703 people
- Sponsor
- Merck Sharp & Dohme LLC
RR DLBCL; PD-1; CD20
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL
This is an open-label, single-arm, and multicenter phase Ⅱ study designed to evaluate the efficacy and safety of F520 (PD-1) combined with F007(rituximab biosimilar) in patients with Relapsed/Refractory diffuse large B-cell…
- Trial name
- NCT05178836
- Testing
- F520+F007
- Volunteers
- 62 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Parkinson's Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
This study will be an open label, dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated daily quaque die (QD) doses given over 21 days (Day 3 to Day 23) to sequential…
- Trial name
- NCT02224664
- Testing
- PF-06649751
- Where
- 17 sites in United States, Belgium
- Volunteers
- 50 people
- Sponsor
- Pfizer
Parkinson Disease
Phase 1/2a Study of ANPD001 in Parkinson Disease
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease.
- Trial name
- ASPIRO (NCT06344026)
- Testing
- ANPD001, Custom Device
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- Aspen Neuroscience
Parkinson's Disease
A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients
The purpose of this study is to determine whether the gastric retentive Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) is more effective than the commercially available immediate release Carbidopa/Levodopa in reducing motor…
- Trial name
- Accordance (NCT02605434)
- Testing
- Accordion Pill™ Carbidopa/Levodopa, Sinemet®
- Where
- 97 sites in United States, Bulgaria and 8 more
- Volunteers
- 420 people
- Sponsor
- Intec Pharma Ltd.
Serotonin Syndrome
Azilect + Antidepressant Chart Review
To identify the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline without antidepressant medications and compared to PD…
- Trial name
- STACCATO (NCT00955604)
- Testing
- Group R+AD Rasagiline + Antidepressant, Group R Rasagiline, Group AD Anti-PD + Antidepressant
- Volunteers
- 1,500 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Idiopathic Parkinson's Disease
Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
The primary objective of this study was to demonstrate that Rotigotine transdermal patch is efficacious in Chinese subjects with advanced-stage Idiopathic Parkinson's Disease as an adjuvant therapy.
- Trial name
- NCT01646255
- Testing
- Rotigotine, L-dopa
- Where
- 24 sites in China
- Volunteers
- 346 people
- Sponsor
- UCB Pharma
PARKINSON DISEASE (Disorder)
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy.
- Trial name
- Vista PD (NCT07804615)
- Testing
- VIM0423
- Where
- 30 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Vima Therapeutics
Parkinson's Disease
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease
REPAIR-PD is a single-center open label pilot, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been…
- Trial name
- REPAIR-PD (NCT03815916)
- Testing
- Gold Nanocrystals
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Clene Nanomedicine
Parkinson Disease
Adaptive Auditive Cueing As a Therapy for Freezing of Gait in Parkinson Patients
The first goal of the study is to investigate whether an algorithm can reliably detect Freezing of Gait (FOG) in Parkinson patients based on participant gait data generated by a pressure insole.
- Trial name
- BioFOGP-IPD1 (NCT04274478)
- Testing
- Auditive cueing
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- Ceriter Nederland BV
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and docetaxel in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received…
- Trial name
- NCT03834506
- Testing
- Pembrolizumab, Docetaxel, Prednisone
- Where
- 215 sites in United States, Argentina and 19 more
- Volunteers
- 1,030 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.